化合物 AZ304【942507-42-8】产品图
文献支持

化合物 AZ304【942507-42-8】

收藏
  • ¥104 - 1896
  • TargetMol
  • T5172
  • 2026年07月07日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • CAS号

      942507-42-8

    • 规格

      1mg/1mLx10mM(inDMSO)/5mg/10mg/25mg/50mg/100mg/200mg

    规格:1mg产品价格:¥104.0
    规格:1mLx10mM(inDMSO)产品价格:¥233.0
    规格:5mg产品价格:¥213.0
    规格:10mg产品价格:¥303.0
    规格:25mg产品价格:¥476.0
    规格:50mg产品价格:¥792.0
    规格:100mg产品价格:¥1272.0
    规格:200mg产品价格:¥1896.0

    Product Introduction

    Bioactivity

    名称 AZ304
    描述 AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
    细胞实验 Briefly, the cells were treated with DMSO or multiple concentrations of AZ304 for 3 days. The cell growth was determined using the CellTiter 96 Aqueous One Cell Proliferation Assay. Percentage of net growth at day 3 (100%) relative to day 0 (0%) was calculated and the concentration of compound required to inhibit growth by 50% (GI50) determined. The assays were done in triplicate across different plates. The proliferation assays in selected colorectal cancer cell lines were measured using an MTT assay. First of all, cultured cells were seeded into 96-well plates (2000–5000 cells per well). After incubation for 24 h, the cells were pretreated with DMSO or AZ304 for 1 h. Then the indicated doses of Cetuximab were added. Cells were incubated for a further 48 or 72 h. For EGF stimulating assay, cells were incubated in reduced serum medium overnight and then treated with AZ304 or AZ304 + EGF (20 ng/ml) for 72 h. Twenty microliters of MTT solution (5 mg/ml) was added to each well followed by 4 h incubation at 37 °C. The cell culture medium was removed and the cells were lysed in 200 μl DMSO and the results were measured using a microplate reader.
    激酶实验 Briefly, the kinase activity of BRAF WT, BRAF V600E, or CRAF was measured using an AlphaScreen assay monitoring MEK1/2 phosphorylation at Ser217/221. For CDK2 and CDK4 kinases, activity was also measured by AlphaScreen, monitoring phosphorylation of biotin Rb peptide at Ser780. Similarly, MAP3K7, CSF1R, and JAK2 kinase activity were measured by phosphorylation of their biotinylated substrates MKK6 kinase-dead protein at Ser271/Thr275, or tyrosine phosphorylation of pEY or Tyk2 Tyr1054/1055 peptides, respectively. CSK, IGF1R, EGFR, FGFR1 and SRC kinase activity was measured using a sandwich ELISA detecting phosphorylated poly EAY peptide with a HRP conjugated phosphotyrosine antibody and TMB substrate, while p38 kinase activity was measured by monitoring phosphorylation of MBP protein with radiolabeled 33P-ATP in a filter binding format. All assays were screened under respective ATP Km conditions and inhibitor IC50s were derived from either 5 (RAF kinases, CDK2, CDK4, MAP3K7, JAK2), 10 (CSK, IGF1R, EGFR, FGFR1, SRC) or 11 (p38, CSF1R) point compound dose response.
    动物实验 Female 4–6 weeks old athymic BALB/c nude mice were purchased from Shanghai SLAC Laboratory Animal Centre. RKO/Caco-2 cells (1 × 10^7) in 200 μl PBS were injected subcutaneously into the right scapular region of mice. After the average tumour size reached 150 – 200 mm^3, animals were randomly divided into 4 groups, each containing three mice and were treated with vehicle only (CON) which orally received 0.5% HPMC and injected with 0.9% saline, AZ304 only (AZ304 dissolved in 0.5% HPMC, 10 mg/kg by oral gavage twice daily), Cetuximab only (40 mg/kg by intraperitoneal injection twice per week), or their combination (A+C) for 10 days. Tumors were measured with a caliper every 2 days, so did body weights. Tumor volume was calculated using the formula V = 1/2 (width^2 × length). Mice were terminated by CO2 inhalation when the tumor diameters reached 1.5 cm, according to the protocol filed with the Guidance of Institutional Animal Care and Use Committee of China Medical University.
    体外活性 AZ304 showed potent inhibitory activities to the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF in vitro, with IC50 values of 79 nM, 38 nM, and 68 nM, respectively. Consistent with BRAF kinase inhibition in vitro, AZ304 potently reduced ERK phosphorylation (p-ERK), with a mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375; an EC50 of 60 nM was obtained for the wild type BRAF melanoma cell line SK-MEL-31. AZ304 markedly inhibited cell proliferation in mutant BRAF cancer cell lines and effectively reduced cell growth in selected cell lines harboring wild type BRAF/RAS or mutant RAS. The GI50 values ranged from 0.08–7.72 μM in mutant BRAF cell lines, 0.43–11.7 μM in wild type BRAF/RAS cell lines, and 0.9–16.66 μM in mutant RAS cell lines.
    体内活性 Compared with vehicle-treated controls, treatment with AZ304 or Cetuximab alone resulted in reduced tumor growth in both xenograft models. Furthermore, the AZ304 and Cetuximab combination caused dramatic tumour growth inhibition and even shrinking in the Caco-2 xenograft model.
    存储条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
    溶解度 DMSO : 50 mg/mL (110.74 mM), Sonication is recommended.
    10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.43 mM), Sonication is recommended.
    H2O : Insoluble
    Ethanol : 4 mg/mL (8.86 mM), Sonication is recommended.
    关键字 Raf kinases | Raf | p38MAPK | p38 MAPK | p38 | Inhibitor | inhibit | CSF1R | cFms | B-Raf (WT) | B-Raf (V600E) | AZ-304 | AZ304 | AZ 304 | Autophagy
    相关产品 D-Psicose | Guanidine hydrochloride | Naringin | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Hemin | Hydroxychloroquine | Sildenafil citrate | Stavudine | Tamoxifen | Paeonol
    相关库 Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library | Anti-Cancer Compound Library | Bioactive Compounds Library Max | Anti-Colorectal Cancer Compound Library | Kinase Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Pain-Related Compound Library

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    官网有文献
    相关实验
    •  杂环化合物和生物碱-- 杂环化合物

      网络 第十九章 杂环化合物和生物碱 杂环化合物在自然界分布很广,其数量几乎占已知有机化合物的三分之一,用途也很多。许多重要的物质如叶绿素、血红素、核酸以及临床应用的一些有显著疗效的天然药物和合成药物等,都含有杂环化合物的结构。生物碱多是中草药的有效成分,绝大多数是含氮的杂环化合物。本章内容与医学关系密切,具有重要意义。

    • 高能化合物 energy rich compound

          分子中具有高能键的化合物。在生物体内主要有上式(Ⅰ)和(Ⅱ)两种结构的高能化合物。其作用为贮藏能量(例如 ATP、肌酸磷酸)和作为产生 ATP源的中间代谢产物(例如磷酸烯醇丙酮酸)以及合成反应的中间物质(例如酰基辅酶 A),在蛋白质的结构( conformation)变化周期的第一阶段上(例如钠钾 ATP酶的羧基磷酸中间体)也具有重要作用。多数高等化合物具有磷酸基,但也有例外。  

    • 化合物

      由不同种元素组成的纯净物叫做化合物化合物一般有固定的组成。化合物的组成一般可用化学式表示。化合物具有确定的物理性质和化学性质,不同于其组成元素的性质。化合物中的元素不能用简单的机械方法或物理方法分开,而必须用化学方法才能分离。    

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥300
    MedChemExpress LLC
    2025年12月05日询价
    ¥1350
    爱必信(上海)生物科技有限公司
    2026年05月28日询价
    ¥185
    TargetMol中国
    2025年07月12日询价
    ¥615
    上海优宁维生物科技股份有限公司
    2025年08月28日询价
    ¥1500
    广州威佳科技有限公司
    2025年07月13日询价
    文献支持
    化合物 AZ304【942507-42-8】
    ¥104 - 1896